Fergal Hill

Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris.

Noshaq SA is an independent private equity/venture capital firm founded in 1985. Noshaq SA is headquartered in Liege.

Imaxio SA develops biopharmaceutical products. It operates as a biotech company which focuses on vaccines, and based on the combination of commercial and research and development activities. The firm provides its services based on proprietary and Agilent DNA chips, notably CGH micro-array analyses. The company was founded by Christian Pradeyrol and Jean Chatellier in 2000 and is headquartered in Lyon, France.

Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France.

Paras Ltd. provides information management and strategy consultancy services to the energy sector. The company was founded by Hamish Angus Munro Wilson in 1993 and is headquartered in Abingdon, the United Kingdom.

ADC Products (UK) Ltd. operates as a clinical stage biotechnology company. It develops pyrrolobenzodiazepines for antibody-drug conjugation. The company was founded in November 2000 and is headquartered in Reading, the United Kingdom.

Xenva Ltd. provides boutique management services. The company was founded on June 19, 1997 and is headquartered in Hampshire, the United Kingdom.

The Boston Consulting Group & Cie SARL provides management consulting services. Its practice areas include branding, marketing, corporate finance, globalization, and information technology. The company is a subsidiary of The Boston Consulting Group. The firm was founded in 1972 and is headquartered in Paris, France.

Minka Therapeutics SA develops therapeutic products and diagnostic complementary to current antiretroviral therapy in the treatment of AIDS. The firm provides therapeutic and diagnostic solutions for diseases linked to the immune system through its research on immune dysregulations. The company was founded by Patrice Debre, Vincent Vieillard, Michel Klein, Joël Crouzet, and Robert L. Murphy in 2008 and is headquartered in Evry, France.

GlaxoSmithKline Pharmaceuticals SA develops and manufactures pharmaceuticals and vaccines. The company is headquartered in Wavre, Belgium.

MedImmune Pharma BV develops, manufactures and markets formulations for use in immunization programs. It specializes in the production of a vaccine called Amifostine. The company was founded in 1993 and is headquartered in Nijmegen, Belgium.

Tokamak Energy Ltd. provides medical and biotechnology services. It develops the potential to use fusion neutrons for a variety of applications from material treatments to medical applications or low cost hydrogen production. The company was founded by David Richard Kingham, Mikhail Gryaznevich and Alan Sykes in 2009 and is headquartered in Abingdon, the United Kingdom.

Pradeyrol Développement SC operates as an investment holding company. It invests in the biotechnology sector and mainly on molecular diagnostics. The company was founded on August 16, 2007 and is headquartered in Paris, France.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

Unisensor SA is a Belgian biotech company that specializes in improving food safety through screening solutions to detect antibiotics, mycotoxins, and other contaminants. Unisensor is based in Seraing, Belgium. The private company develops innovative, fast, and easy-to-use diagnostic tests that are now connected. The company was founded in 1997 by Benoit Granier, who has been the CEO since then.

Xerys Gestion SASU (Xerys) is a private equity and venture capital firm headquartered in Paris, France. The firm was founded in 2000 by Jacques Simonnet.

Spirogen SARL is a Swiss company. 'The private company is based in Lausanne, Switzerland. The company was founded by Christopher John Martin.

Meissa Vaccines, Inc. operates as a pharmaceutical development company. It focuses on the in-licensing and advancement of vaccines for respiratory syncytial virus. The company was founded by Marty Moore and Roderick Tang in 2014 and is headquartered in South San Francisco, CA.

Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019.

Man & Science NV is a Belgian medical device company that develops a novel, minimally invasive, battery-free neurostimulation system to reduce the pain and frequency of severe headache attacks. The company is based in Mont-Saint-Guibert, Belgium, and has subsidiaries in Norway. The company's therapies allow headache patients to return to a normal, pain-free life. The company's team consists of experienced scientists, engineers, clinical research specialists, business experts, and successful start-up founders and entrepreneurs. The company was founded in 2011 by Robert Taub, and Fabian Suarez Gonzalez has been the CEO of the company since 2022.

Tagworks Pharmaceuticals BV is a Dutch precision therapy company that develops a new standard of care for patients suffering from severe diseases, including cancer. Tagworks Pharmaceuticals is based in and the Netherlands. The company leverages its technology platform, which is protected by a broad patent estate, to pioneer the click-to-release approach. Tagworks is developing a pipeline of click-cleavable therapies, including its lead program, TGW101, an antibody-drug conjugate targeting TAG72. The company's technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. The company was founded in 2011 by Raffaella Rossin, Zach Taylor, Marc Robillard, and Marc Robillard has been the CEO since 2011.

Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom.

VaxEquity Ltd. is a UK biotechnology company founded in 2020 by Professor Robin Shattock, the head of immunology of infection at Imperial College and Morningside. The company is based in Little Chesterford, UK. The British company is developing transformative RNA therapeutics and vaccines using its next-generation self-amplifying RNA platform called SARNA. The platform provides extended duration of protein expression, enabling lower doses to be used for vaccines and higher protein levels to be achieved for therapeutics. VaxEquity is pioneering a next-generation approach by modifying its SARNA to modulate the innate immune response and thereby overcoming current limitations. The flexibility of the company's platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale.

EXO Biologics SA operates as a Belgian biotechnology company. The company is based in Liege, Belgium. The company was founded in 2019. Hugues Wallemacq has been the CEO of the company since 2021.